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Abstract We determined the binding domains of safentanil and 
lofentanil in the Ix opioid receptor by comparing their binding 
affinities to seven ~8 and six IX/~: chimeric receptors with those to 
Ix, 8 and ~ opioid receptors. TMHs 6 and 7 and the e3 loop of the 
Ix opioid receptor were important for selective binding of 
sufentanil and Iofentanil to the Ix over the ~ receptor. TMHs 
1-3 and the el loop of the Ix opioid receptor conferred binding 
selectivity for sufentanil over the 8 receptor. Thus, the region that 
conferred binding selectivity for sufentanil differs, depending on 
chimeras used. In addition, the interaction TMHs 1-3 and 
TMI-Is 6-7 was crucial for the high affinity binding of these two 
ligands. These two regions are likely to contain sites of 
interaction with the ligands or to confer conformations pecific 
to the Ix receptor. 
Key words: Sufentanil; Lofentanil; Chimeric receptor; 
Opioid receptor; Structure-function relationship 
1. Introduction 
Opiate and opioid drugs, acting on membrane-bound recep- 
tors, produce many pharmacological effects. The existence of 
at least three types of opioid receptors Ix, 8 and ~ - has been 
demonstrated [1]. Mu opioid receptors mediate many effects 
of opiates and opioid compounds, including, most notably, 
modulation of pain perception and euphoria [1]. Activation 
of IX opioid receptors couples via pertussis toxin-sensitive G 
proteins to various effectors including adenylate cyclase and 
K + and Ca 2+ channels [1]. 
Following the cloning of the 8 receptor [2,3], several labora- 
tories reported cloning of the IX opioid receptor [4-12]. In 
addition, the ~c opioid receptor has been cloned [13-21]. All 
three opioid receptors contain seven putative transmembrane 
helices (TMHs), a common structural motif of G protein- 
coupled receptor superfamily. Sequence comparison among 
the three types of opioid receptors hows substantial diver- 
gence in the N- and C-terminal domains as well as extracel- 
lular loops, while sequences within TMHs and intracellular 
loops are very similar. These divergent sequences may contrib- 
ute to the binding of type-selective ligands. The availability of 
IX, 8 and ~ opioid receptor clones permits identification of the 
structural basis of binding selectivity of these receptors at the 
molecular level. 
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Deletion of 64 N-terminal amino acids and 33 C-terminal 
amino acids of the g receptor did not affect binding of ago- 
nists and antagonists [6,22], indicating that the N- and C- 
terminal domains do not contribute to ligand binding. 
Chimeric g/K, g/8 and 8/~ receptors have been very useful in 
delineation of ligand binding domains of IX, 8 and ~ receptors. 
For the IX receptor, using IX/K chimeras, we [23,24] demon- 
strated that the TMHs 6 and 7 and the third extracellular 
(e3) loop of the g receptor were important for binding of 
selective agonists, such as DAMGO, sufentanil, PL017 and 
morphine, as well as covalent binding of the irreversible li- 
gand [3-funaltrexamine. Similar results were reported for 
DAMGO binding by Minami et al. [25], who used g/~ chi- 
meras. In contrast, Onogi et al. [26] and Fukuda et a1.[27] 
reported that the determinant of selectivity of the g receptor 
for DAMGO was located in the first extracellular (el) loop, 
based on analysis of binding of DAMGO to a series of chi- 
meric g/8 opioid receptors. The el loop was also partly in- 
volved in selectivity of other peptide ligands, but not nonpep- 
tide ligands [26]. Major determinants for binding of morphine 
are within TMHs 5-7 as determined by binding to g/8 chi- 
meras [27]. Thus, in the case of DAMGO, regions conferring 
specificity in the IX receptor are different, as determined from 
IX/~ and g/8 chimera studies. On the contrary, for morphine, 
the regions are similar, whether determined from IX/~ or g/8 
chimera studies. 
Sufentanil and its analog lofentanil are narcotic analgesics 
with high potency. Both are thought to act on IX opioid re- 
ceptors and display morphine-like side effects. Chemically, 
these two drugs are phenylpiperidines and they are distinctly 
different from morphine and oxymorphone, which are mor- 
phinans. In this study, we determined the region in the IX 
receptor that conferred selectivity for the binding of sufentanil 
and lofentanil by examining their binding to chimeric g/8 
receptors constructed from cloned rat g and mouse 8 opioid 
receptors [3,4] and to chimeric g/~: receptors generated from 
cloned rat Ix and ~ opioid receptors [4,14]. 
2. Materials and methods 
2.1. Construction fchimeric gl~ and g/8 receptors 
Six chimeric p./~: receptors, chimeras I, II, III, IV, XI, and XII, were 
constructed from rat g and ~c opioid receptors [4,14]. Chimera I (ami- 
no acid (aa) Kl-186/g194~267/~:263-380) and chimera II (aa gl 193/ 
K187-262/g269 398) were generated by switching the fragments con- 
taining the C-terminal half of the TMH 4, the e2 loop and the TMH 
5. Chimera III (aa •1 141/g151-398) and chimera IV (aa p.1 150/ 
~c142 380) were constructed by swapping the regions from the N-ter- 
minus to the start of the TMH 3. Chimera XI (aa lal-268/~:263-380) 
and chimera XII (aa ~1 262/p.269-398) were generated by exchanging 
the regions from the middle of the third intracellular (i3) loop to the 
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C-terminus. Details of generation of g/K chimeras were described pre- 
viously [28]. Schematic drawings of chimeras are shown in Table 1. 
Seven chimeric pJ8 receptors (8/p.1, ~/81, p./83, 8/~t4, ~4,  5/kt5 and 
~/83/t167) were constructed from the mouse 5 and the rat ~t opioid 
receptors [3,4]. Chimeras ~5/[zl (aa 81 75/1195-398) and la/51 (aa 1.tl-94/ 
576-372) were constructed by swapping the regions from the N-ter- 
minus to the start of the first intracellular (il) loop. Chimera kt/53 (aa 
ktl-153/5135-372) was generated by combining the region from the N- 
terminus to the end of TMH 3 of the p. receptor with a fragment of 
the 8 receptor from the end of TMH 3 to the C-terminus. Chimeras 8/ 
I.t4 (aa 81 187/~t207-398) and pJ54 (aa ml-206/~188-372) were con- 
structed by exchanging the segments from the N-terminus to the be- 
ginning of the second extracellular (e2) loop. Details of generation of 
these five la/8 chimeras has been described [29]. 
Chimera 8/p.5 (aa 81-260/kt280-398) was constructed by combining 
the region from the N-terminus to the beginning of TMH 6 of the 5 
receptor with the segment from the beginning of TMH 6 to the C- 
terminus of the Ix receptor. For this purpose, a MluI restriction en- 
zyme site was created at Thr-279 and Arg-280 of the Ix receptor and at 
the corresponding Thr-260 and Arg-261 of the 5 receptor using the 
Promega palter-1 site-directed mutagenesis protocol. 
Chimera ~/63/Ix67 (Ixl-153/5135-260/Ix280-398) was constructed on 
the basic structure of pJfi3 with the fragment from the beginning of 
TMH 6 to the C-terminus of the ~t receptor. Chimera [.t/83/~t5 was 
generated from chimeras ~83 and 5/~t5. Chimera Ix/83 was treated 
with HindlII and BgllI and chimera 8/I.t5 with BgllI and XbaI. The 
fragments from N-terminus to Lys-233 of the Ia/53 and that from I1e- 
215 to C-terminus of the 8/p.5 were isolated and ligated into the 
plasmid vector pcDNA3 treated with HindlII and XbaI. Schematic 
drawings of I-d5 chimeras are shown in Table 2. 
Nucleotide sequence determination [30] was performed to ensure 
successful generation of chimeras. 
2.2. Stable expression in Chinese hamster ovary (CHO) cells 
CHO cell lines stably expressing each of the seven chimeric p./~5 
receptors, ~t and 5 receptors were established as described [31]. 
2.3. Transient expression in COS-1 cells 
Wild types and chimeric Ix/~ receptors were transfected into COS-1 
cells with DEAE-dextran-chloroquine m thod [32] as described [28]. 
Cells were harvested for 48-60 h following transfection. 
2.4. Membrane preparation 
Membranes were prepared from CHO cells and COS-1 cells as 
described previously [29]. Protein contents of membranes were deter- 
mined by the BCA method of Smith et al. [33] with bovine serum 
albumin as the standard. 
2.5. Opioid receptor binding 
Opioid receptor binding was conducted with [3H]diprenorphine in 
TEL (50 mM Tris-HC1, 1 mM EGTA and 5 laM Leupeptin). (--)Na- 
loxone (10 ktM) was used to define nonspecific binding. Saturation 
experiments were performed with various concentrations of 
[3H]diprenorphine (ranging from 0.05 nM to 5 nM) as described 
[28,29]. Inhibition of [3H]diprenorphine binding was performed with 
[3H]diprenorphine at a concentration close to its Kd for each receptor 
and various concentrations of sufentanil or lofentanil. Binding was 
conducted at 0°C for 2 h in duplicate in a volume of 1 ml with 30-60 
p.g protein. Bound and free ligands were separated by rapid filtration 
under reduced pressure over GF/B filters pre-soaked with 0.5% poly- 
ethyleneimine. Binding data were analyzed with EBDA and LIGAND 
programs [34]. 
2.6. Materials 
[3H]Diprenorphine (35 Ci/mmol) was purchased from Amersham 
(Arlington Heights, IL). Sufentanil and lofentanil were generously 
provided by Janssen Research Foundation (Beerse, Belgium). The 
vectors pRc/CMV and pcDNA3 were purchased from Invitrogen 
(San Diego, CA); pfu DNA polymerase and the vector pBK-CMV 
from Stratagene (San Diego, CA). 
3. Results and discussion 
Saturation binding of [3H]diprenorphine to the chimeric p/~: 
199 
and pJfi receptors was performed and compared with IX, K and 
~5 opioid receptors. All six chimeric p/n and seven Ix/5 receptor 
bound [3H]diprenorphine with high affinity with Ka values 
ranging from 0.14 to 1.2 nM (Ka= 1.22+0.06 nM for ~i/kt5 
and Ka = 0.15 +0.02 nM for ~83/IX5, n= 3 each) ([28,29] for 
all others). These Ko values are similar to those of IX, ~c and 6 
receptors, suggesting that these chimeric receptors retain gen- 
eral structural conformation of opioid receptors. 
Competitive inhibition of [ZH]diprenorphine binding by su- 
fentanil or lofentanil to the six chimeric g/n receptors was 
performed and Ki values were determined and compared to 
those of IX and n opioid receptors (Table 1; Fig. 1Fig. 2). 
Sufentanil bound to the IX receptor with Ki value of 
0.71 + 0.11 nM (n= 3), about 200-fold higher affinity than it 
did to the n receptor (Ki = 138 +45 nM, n=3).  Chimera II 
bound sufentanil with high affinity, similar to the IX receptor, 
and XII had an affinity ,-, 7 times lower than the IX receptor. 
In contrast, I and XI had low affinity for sufentanil, similar to 
the n receptor. Chimera III and IV had intermediate affinity 
for sufentanil, being 53 and 21 times lower than that of the la 
receptor. 
Lofentanil has a Ki value of 0.25 + 0.08 nM (n = 3) for the Ix 
receptor, about 50-fold higher than that for the ~: receptor 
(Ki = 11.8 + 0.4 nM, n = 3). Like sufentanil, lofentanil bound 
to chimeras II and XII  with similar high affinity as it bound to 
the Ix receptor. Chimera I had low affinity, similar to the 
receptor. Chimeras III, IV and XI had intermediate affinity 
for lofentanil, with 3-9 times lower affinity than the ~t recep- 
tor. 
Thus, TMHs 6 and 7 and the e3 loop of the Ix opioid 
receptor appear to be important for the selective binding of 
sufentanil and lofentanil over the n receptor. In addition, the 
findings that chimera II bound sufentanil and, to a less extent, 
Table 1. Ki valus of sufentanil and lofentanil for inhibition 
of [3H]diprenorphine binding to the rat ~t and ~z opioid 
receptors and chimerec ~ receptors. Ki value were derived 
from results shown in figure 1 & 2. Data are shown as 
mean + s.e.m, of three independent determinations in duplicate. 
Sufentanil  Lofentani l  
Ki (nM) Ki (nM) 
~a~ 0.71 +0.11 a 0.25+0.08 
1~ ,~J~ 138 + 45 a 11.8+0.4 
I ~ J~ 153 + 25 4.35+0.24 
II ~ 0.30-+0.01 0.29_+0.14 
III ~ 37.8_+8.3 1.34_+0.10 
IV ~ i  15.0+1.0 0.82+0.18 
XI ~ 85.0+17.0 a 2.15+0.15 
XII ~ 4.70-+0.70 a 0.34+0.11 
a Xue et al. 1995. 
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Table 2. Ki values of sufentanil for inhibition of 
[3H]diprenorphine binding to the rat IX and mouse 8 opioid 
receptors and chimeric W8 receptors. Ki values were 
derived from results hown in Figures 3. Data are shown as 
mean + s.e.m, of three independent determinations i  duplicate. 
Sufentanil 
Ki (nM) 
,U, }o{~ 0.61 _+ 0.15 
(~ ~ 148.3 + 19.7 
8/gl ~d~J] 4.6 _+ 0.9 
g/81 U~ 153.6 + 25.0 
W83 0.83_+ 005 
8/p4 ~ 6.oo + 1.5o 
p/ 4 49.0  +_ 98 
(~/~5 ~ 26.0 _+ 1.90 
g/83/g67 ~ .~J]  3.17 _+ 0.56 
lofentanil with higher affinity than chimeras IV and XII and 
with the same high affinity as the IX receptor indicate that the 
interaction TMHs 1-3 and TMHs 6 and 7 is crucial for the 
high affinity binding of these two ligands. Since similar re- 
gions are important for the binding of sufentanil and lofenta- 
nil, it is likely that sufentanil and lofentanil bind to the bind- 
ing pocket of the IX receptor in a similar manner. 
Similar competitive inhibition of [aH]diprenorphine binding 
by sufentanil were carried out with chimeric g/8 receptors and 
ix and 8 opioid receptors and Ki values were determined (Ta- 
ble 2 and Fig. 3). Chimera ~83 displayed high binding affinity 
to sufentanil, similar to the g receptor. 8/IXl, 8/g4 and ~83/ 
IX67 exhibited 5-10-fold lower affinity than of the IX receptor, 
but 25-50-fold higher affinity than the 8 receptor. Chimeras 
54 and 8/IX5 bound sufentanil with lower affinities than the IX 
receptor by 40-80 fold. Chimera ~81 had a Ki value similar 
to that of the 8 receptor. Since lofentanil has only a 20-fold 
selectivity for the IX over 8 receptor, with Ki values of 0.25 nM 
and 5.1 nM, respectively, its binding to p/8 chimeras was not 
analyzed. 
Thus, TMHs 1-3 and the el loop of the IX opioid receptor 
appear to confer binding selectivity for sufentanil over the 8 
receptor. While TMHs 6 and 7 do not play an important role 
in selective binding of sufentanil to the IX over 8 receptor, the 
interaction between TMHs 1-3 and TMHs 6 and 7 is also 
important for the high affinity binding of sufentanil. 
These results indicate that the region in the IX opioid recep- 
tor conferring selectivity for sufentanil over the ~c receptors i  
TMHs 6-7 and e3 loop, whereas ufentanil distinguishes be- 
tween IX and 8 receptors at the region of TMHs 1-3 and el 
loop. Interestingly, we and others have observed a similar 
phenomenon regarding the binding of DAMGO [23,25-27]. 
DAMGO was found to distinguish between IX and ~ receptors 
at the region of TMHs 6-7 and the e3 loop. In contrast, 
DAMGO distinguished between IX and 8 receptors at the re- 
gion of the el loop. It is, thus, likely that the binding pocket 
for sufentanil n the IX receptor is somehow similar to that for 
DAMGO. There may be a few of amino acids located in the 
TMHs 6-7 including the e3 loop and TMHs 1-3 including the 
el loop of the IX receptor, which are responsible for selective 
binding of these ligands to over the ~c receptor and over the 8 
receptor, respectively. Alternatively, it is likely that TMHs 6-7 
of the IX receptor provides the conformation of the IX opioid 
receptor to ~:  chimera XII that favors high affinity binding 
of tx selective ligands, including morphine, DAMGO and su- 
fentanil [23]. Similarly, TMHs 1-3 of the IX receptor may 
make p J83 assume more IX receptor conformation that binds 
IX ligands with high affinity. 
In addition, particularly by using IX/~c himeric receptors, we 
observed that the interaction between TMHs 1-3 and TMHs 
6 and 7 was important for the high affinity binding of sufen- 
tanil and lofentanil. This may be due to some inter-helical 
interactions creating a proper local conformation which is 
crucial for the high affinity binding of selective ligands to 
the IX receptor. Interhelical interactions have been demon- 
strated between an Asp in the TMH 2 and an Asn in the 
TMH 7 in the 5HT2A receptor [35] and between an Asn re- 
sidue in the TMH 2 and an Asp in the TMH 7 in the gona- 
dotropin-releasing hormone receptor [36]. These interactions 
are shown to be important in maintaining proper receptor 
conformations for coupling to G proteins [35] or binding 
[36]. Besides interactions between specific amino acids, as 
pointed out by Kobilka et al. [37], the arrangement of 
TMHs relative to each other was most likely to be determined 
by interactions among various charged, uncharged polar and 
nonpolar amino acid residues and possible disulfide bond for- 
mation. The adjacent TMHs presumably have been evolved to 
have minimal steric hindrance and most favorable electro- 
static interactions. Such interactions may be disrupted in 
some chimeric receptors. 
Chimera p/54 had lower affinities for sufentanil than ~83, 
although ~54 had more IX sequence than IX/83. This finding is 
reminiscent of our observation on SUPERFIT [29]. Despite 
the fact that 8/IX4 had more 8 sequence than 8/IX3, chimera 8/ 
IX4 had a lower affinity for SUPERFIT than 8/IX3. It is likely 
that the TMH 4 of 8 receptor may not be as compatible with 
the TMH 5 of the IX receptor and vice versa. Chimeras that 
contain TMH 4 of one receptor and TMH 5 of the other 
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Fig. 1. Comparison of competitive inhibition by sufentanil of 
[3H]diprenorphine binding to cloned rat tx and ~ opioid receptors 
and p/~c himeras. Ki values of sufentanil are shown in Table 1. 
Each curve represents one of the three experiments performed. 
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2. Comparison of competitive inhibition by lofentanil of 
[aH]diprenorphine binding to cloned rat kt and K opioid receptors 
and ta/~ chimeras. Ki values of lofentanil are shown in Table 1. 
Each curve represents one of the three experiments performed. 
(such as ~fi4 and 8/kt4) do not have the proper local confor- 
mation to bind sufentanil and SUPERFIT  with high affinity, 
although both chimeras bound [3H]diprenorphine, a nonselec- 
tive ligand, with high affinity. Law et al. found that, in gen- 
eral, 6/~t4 had lower affinity for 8 selective ligands than 6/~t3 
(unpublished observations). However, /a/83 did not seem to 
have higher affinities for I.t ligands than pJ~4. Thus, this phe- 
nomenon might be limited to sufentanil and its analogs. 
In conclusion, the regions conferring selectivity of sufenta- 
nil and lofentanil for the ~t over the 8 receptor are different 
from those for the p. over the ~ receptor. These regions of the 
~t receptor are likely to contain sites of interaction with the 
ligands or to confer the ~ receptor conformation. Chimeric 
receptor studies provide starting points for future studies on 
identification of amino acid residues as binding epitopes. 
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